Wuxi Pushing Ahead with $3bn Go-Private Deal
This article was originally published in Scrip
Executive Summary
Despite the market turmoil on China’s stock exchanges since June, US-listed Chinese healthcare-related companies have not stepped back from privatization plans and the consideration of floating again on Chinese bourses, given the encouraging policies and promising development environment in the country.
You may also be interested in...
China Sets The Stage For Its Innovation Entrance
China is coming up fast on the innovation curve as a result of political will and a healthy ecosystem that supports R&D. It will take time to challenge the major players from the US and Europe, but there are few that doubt China can, eventually, do so.
Key Role For China As Sanofi’s Emerging Markets Business Grows
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Deal Watch: Avid Transitions Into CDMO By Offloading Cancer Program To Oncologie
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.